Mr Leland Lamar Wince, MD in Albany, IN - Pediatrics

Mr Leland Lamar Wince, MD is a Pediatrics physician based in Albany, Indiana. Mr Leland Lamar Wince is licensed to practice in Indiana (license number 01020366A) and his current practice location is 8040 East Clifton Rd, Albany, Indiana. He can be reached at his office (for appointments etc.) via phone at (765) 288-3072.

NPI number for Mr Leland Lamar Wince is 1053719302 and his current mailing address is 8040 E. Clifton Rd, Albany, Indiana. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1053719302.

Contact Information

	Mr Leland Lamar Wince, MD
	8040 East Clifton Rd, Albany, IN 47320
	(765) 288-3072
	Not Available

Physician's Profile

Full Name	Mr Leland Lamar Wince
Gender	Male
Speciality	Pediatrics
Location	8040 East Clifton Rd, Albany, Indiana
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1053719302
Provider Enumeration Date: 12/18/2014
Last Update Date: 12/18/2014

Medical Identifiers

Medical identifiers for Mr Leland Lamar Wince such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1053719302	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208000000X	Pediatrics	01020366A (Indiana)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Leland Lamar Wince is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Leland Lamar Wince, MD 8040 E. Clifton Rd, Albany, IN 47320 Ph: (765) 288-3072	Mr Leland Lamar Wince, MD 8040 East Clifton Rd, Albany, IN 47320 Ph: (765) 288-3072

News Archive

Higher ‘mutational burden' of tumors predicts success rate with cancer immunotherapies

The "mutational burden," or the number of mutations present in a tumor's DNA, is a good predictor of whether that cancer type will respond to a class of cancer immunotherapy drugs known as checkpoint inhibitors, a new study led by Johns Hopkins Kimmel Cancer Center researchers shows.

Estrogen use lowered one risk factor for heart disease among some younger postmenopausal women

A follow-up study to the federally funded Women's Health Initiative should help allay one concern in a subset of women in their 50s who are considering taking estrogen to relieve hot flashes.

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

Cationic peptides inhibit SARS-CoV-2 cell entry

In a paper recently published in Pathogens, in silico affinity studies by researchers at the University of Illinois, USA, reveal several potential peptide binding sites required for HS-spike protein and ACE2-spike protein bond formation, and synthesis of suitable peptide inhibitors reveals impaired SARS-CoV-2 cell entry.

Mr Leland Lamar Wince, MD - Pediatrics in Albany, IN